Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.
基於Veldona的新型潛在動物藥物的臨床研究有望擴大VELDONA的市場。
This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025.
該臨床試驗的目標是到2024年底完成30名受試者的入組，試驗報告將於2025年第一季度完成。
SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"), today announced it has enrolled the first subject for its Taiwanese clinical study of VELDONA-based animal drug in treating feline chronic gingivostomatitis ("FCGS"), a serious and painful chronic cat oral disease characterized by inflammation or abnormal proliferation in the oral cavity. Dosing of the first subject is expected to occur on July 26, 2024.
加利福尼亞州聖地亞哥/ACCESSWIRE/2024年7月23日/Ainos, Inc.（納斯達克股票代碼：AIMD，AIMDW）））（“Ainos” 或 “公司”），一家專注於新型人工智能即時測試（“POCT”）和低劑量干擾素療法（“VELDONA”）的多元化醫療保健公司，今天宣佈其臺灣VelDONA臨床研究入組了第一位受試者基於Dona的動物藥物，用於治療貓慢性牙齦炎（“FCGS”），這是一種嚴重而痛苦的慢性貓口腔疾病，其特徵是口腔發炎或異常增生。預計將在2024年7月26日對第一名受試者進行給藥。